STAT+: A Roche treatment fails to slow cognitive decline in patients with inherited form of Alzheimer’s disease
Roche reported negative results Thursday from a long-running clinical trial investigating an experimental antibody treatment in people born with an inherited form of early onset Alzheimer’s disease.
The Swiss pharma giant has been running the Phase 3 clinical trial for more than a decade, aiming to show that an antibody called crenezumab that targets toxic brain plaques might slow or even prevent Alzheimer’s disease in people born with a specific genetic mutation that typically causes cognitive impairment to begin around age 44.
Continue to STAT+ to read the full story…
